Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
American Assets Trust, Inc., a US-based real estate investment trust (REIT), announced its Q2 2026 earnings release for July 28, 2026, followed by a conference call on July 29. The company manages a diversified portfolio of office, retail, multifamily, and mixed-use properties primarily located in high-barrier U.S. markets.
Alcon and RxSight have entered a non-exclusive collaboration to co-develop adjustable post-operative light adjustable presbyopia-correcting intraocular lenses (PCIOLs) that allow fine-tuning of visual outcomes after cataract surgery. RxSight will receive a $60 million upfront payment and up to $140 million in milestone payments, with Alcon leading …
Joseph Ronald Catapano, Teladoc Health's Chief Accounting Officer, executed a sale of 653 common shares on July 2, 2026, totaling $5,942. The transaction, priced at $9.10 per share, was necessitated by tax withholding requirements tied to the vesting of restricted stock units. This event occurs against a backdrop of Teladoc's stock performance, whi…
DoorDash, Inc. (NASDAQ:DASH) director Andy Fang executed a sale of 5,000 Class A Common Stock shares on July 1, 2026, valued at $925,096. The transaction, conducted under a Rule 10b5-1 trading plan established on March 6, 2026, followed the conversion of 5,000 Class B shares into Class A shares. Fang's indirect holdings remain substantial through h…
Bren D. Higgins, Executive Vice President and Chief Financial Officer of KLA Corp (NASDAQ: KLAC), completed a stock sale on July 2, 2026, disposing of 27,701 shares at an aggregate value of approximately $7.36 million. The transaction was executed at $265.69 per share under the terms of a Rule 10b5-1 trading plan adopted in May 2025. While the sale…
Commerce.com, Inc. (NASDAQ:CMRC) Chief Financial Officer and Chief Operating Officer Daniel Lentz executed a sale of company stock on July 1, 2026. The transaction occurred as the company integrates PayPal’s Store Sync and navigates an unsolicited acquisition proposal from Rezolve Ai. The sale provides a snapshot of insider activity against a backd…
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, a deal that equates to roughly $10.0 billion in equity value and about $8.8 billion net of cash expected to be acquired. The boards of both companies have given unanimous approval; the transaction is anticipated to close in the third quarter of 2026…
Three individuals familiar with the matter say the Cybersecurity and Infrastructure Security Agency (CISA) has been using Anthropic’s AI model Mythos to examine government software repositories for security flaws. The work is reportedly conducted by CISA’s Attack Surface Evaluation team and has uncovered numerous vulnerabilities, while the broader …
SEALSQ Corp delivered preliminary H1 2026 revenue of approximately $11 million, a 120% increase compared to H1 2025, driven by growth in Vault-IC secure elements, PKI subscriptions, and contributions from the IC’ALPS acquisition. The company reaffirmed its FY 2026 revenue guidance of 50%-100% growth, supported by an active $225 million pipeline and…
Aligos Therapeutics received a $25 million upfront payment after granting Xiamen Amoytop Biotech exclusive Greater China rights to pevifoscorvir sodium, triggering a 21% jump in after-hours trading. The agreement includes up to $420 million in milestones and tiered royalties, and the therapy earned Breakthrough Therapy Designation from China’s regu…
Context Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in T cell engaging bispecific antibodies for solid tumors, announced its addition to the Russell 2000 and Russell 3000 Indexes effective June 26, 2026. This inclusion reflects the company's growing market presence and provides greater exposure to institutional invest…
Frederick Blair Wimbush, a director at AH Realty Trust, Inc. (NASDAQ:AHRT), has increased his direct ownership in the real estate investment trust through a series of stock purchases and unit conversions in early July 2026. The transactions, executed through a broker-sponsored dividend reinvestment program and the conversion of Time-Based Long-Term…
Sprout Social, Inc., a Nasdaq-listed AI-powered social intelligence platform company, announced it will report its financial results for the second quarter ending June 30, 2026, on August 6, 2026, after market close. The company will hold a conference call and webcast to discuss results and business highlights, and encourages investors to follow it…
Valley National Bancorp announced it will release its Q2 2026 earnings before market open on July 23, 2026. CEO Ira Robbins will host a conference call to discuss results. The bank offers diversified consumer, commercial, and wealth management services across multiple U.S. states with over $64 billion in assets.
PennantPark Floating Rate Capital Ltd., a NYSE-listed business development company focused on middle-market U.S. private companies, announced it will release its third fiscal quarter 2026 results after market close on August 10, 2026, followed by a conference call on August 11, 2026 to discuss financial results. The company primarily invests in flo…
Kalaris Therapeutics appointed Laurie Keating, an accomplished biopharmaceutical executive with extensive legal and operational expertise, to its Board of Directors effective August 1, 2026. Laurie Keating's addition comes as Kalaris advances its clinical-stage treatment TH103 for retinal diseases. The company also announced the departure of Morana…
Navitas Semiconductor announced it will release its financial results for the second quarter of 2026 on July 27 after market close. The company's CEO and CFO will host an earnings call to discuss results and outlook. Navitas specializes in next-gen GaN and SiC semiconductor technologies for AI data centers, energy infrastructure, and industrial app…
Longeveron Inc. announced the appointment of Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026. Ms. Washburn brings over 20 years of experience in pharmaceutical and biotech finance leadership. This leadership transition occurs as Longeveron anticipates top-line Phase 2b clinical trial results for its lead…
Organogenesis Holdings Inc. announced that the FDA has accepted for review its Biologics License Application for ReNu®, a biologic therapy aimed at treating pain in symptomatic knee osteoarthritis. The FDA set a target action date of April 24, 2027. ReNu® is poised to become the first non-surgical biologic treatment for knee OA, a condition affecti…
Aligos Therapeutics announced it has received a $25 million upfront payment from an exclusive license agreement with Xiamen Amoytop Biotech for pevifoscorvir sodium in Greater China. The drug has also been granted Breakthrough Therapy Designation by China's regulatory authorities, potentially expediting its approval for treating chronic hepatitis B…
PennantPark Investment Corporation (NYSE: PNNT), a business development company focused on U.S. middle-market private companies, will release its financial results for the third fiscal quarter ended June 30, 2026 on August 10, 2026, after market close. The company will host a conference call on August 11 to discuss the results, inviting all interes…
Encore Capital Group, a specialty finance company focused on consumer debt recovery, announced it will release its second quarter 2026 financial results on August 5, 2026. The company will host a conference call and webcast for investors on the same day to discuss the results.
Elicio Therapeutics has successfully closed a $15 million registered direct offering led by new institutional investors to fund its clinical programs, primarily focusing on the Phase 1 development of ELI-002 7P for metastatic pancreatic ductal adenocarcinoma (PDAC). The company plans to leverage the proceeds to advance its immunotherapy pipeline ta…
Abivax SA, a clinical-stage biotech company listed on Nasdaq and Euronext Paris, announced the closing of its public offering raising approximately $920 million gross. The net proceeds of about $874 million will finance its operations until late 2029, supporting advancement of its lead drug candidate in Phase 3 trials for ulcerative colitis and oth…
Control Empresarial de Capitales S.A. de C.V., a major shareholder linked to the Slim Family, executed a divestment of 200,000 Class A Common Shares in PBF Energy Inc. (NYSE:PBF) on July 1, 2026. The transaction, valued at $9,388,660, occurred as PBF Energy trades near its 52-week high, reflecting complex dynamics in the refining sector. This sale …
